A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
INTRODUCTION: Alcohol use disorder (AUD) is a massive burden for the individual, relatives and society. Despite this, the treatment gap is wide compared with other mental health disorders. Treatment options are sparse, with only three Food and Drug A…
Adipose tissue is a central player in energy balance and glucose homeostasis, expanding in the face of caloric overload in order to store energy safely. If caloric overload continues unabated, however, adipose tissue becomes dysfunctional, leading to…
BACKGROUND: Glucagon-like peptide 1 receptor agonists have shown promising results in obesity treatment. In France, semaglutide 2.4-mg (Wegovy) has benefited from an early-access program from July 2022 to September 2023. OBJECTIVE: This study aimed t…
Peripheral artery disease (PAD) is associated with a high risk of cardiovascular events. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiovascular benefit in patients with diabetes, their role in patients with PAD wi…
Cardiovascular-Kidney-Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven by shared pathophysiological mechanisms. However, this framework notably excludes the…
BackgroundAlzheimer's disease (AD) causes cognitive function disorder and has become the preeminent cause of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists, semaglutide, have shown positive effects on promoting the cognitive function. Ho…
Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, represents one of the leading causes of chronic liver disease worldwide. Its high prevalence is driven by insulin resistance, obesity and type 2 diabetes (T2D) and is as…
INTRODUCTION: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood. METHODS: Patients with IBD treated with GLP1-RA were retrospectively identified f…
To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in subjects with type 2 diabetes (T2DM). Electronic databases were searched from inception to 2nd October 2024 for randomised controlled trials comparing GLP-1RAs…
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used due to their significant anti-atherosclerotic, cardiovascular, and renoprotective benefits. However, potential adverse effects must also be considered. Here, we present a rare case of…
BACKGROUND: Bariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain. Glucagon-like peptide-1 receptor agonists (arGLP-1) have emerg…
AIM: Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clin…
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used as anti-obesity agents, there are individual differences between these agents, thus making it difficult to achieve optimal treatment efficacy. This study aimed to determine…
OBJECTIVES: The objective of this study was to estimate comprehensive value of semaglutide in the Medicare population for current and future FDA-approved indications. METHODS: We used data from government reports, published clinical studies, and real…
BACKGROUND: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, for weight management has raised new considerations in aesthetic surgery. While these drugs offer significant preoperative weight loss benefits,…
OBJECTIVE: This study aims to systematically evaluate and perform a systematic review and network meta-analysis comparing the comprehensive cardiovascular protective effects of various glucagon-like peptide-1 receptor agonists (GLP-1RAs), focusing on…
Therapeutic peptides' physical and chemical stability is of significant interest to the pharmaceutical industry. This study examines the effects of pH, temperature, and buffer strength on semaglutide (SEMA) stability using two orthogonal stability-in…